Table 1 Baseline characteristics of the study population overall and by treatment group
Characteristic | All | Vitamin D | No vitamin D | Omega-3 | No omega-3 | SHEP | No SHEP |
|---|---|---|---|---|---|---|---|
(n = 777) | (n = 397) | (n = 380) | (n = 385) | (n = 392) | (n = 388) | (n = 389) | |
Chronological age (years), mean (s.d.) | 75.47 (4.47) | 75.55 (4.54) | 75.39 (4.40) | 75.14 (4.20) | 75.80 (4.70) | 75.44 (4.48) | 75.50 (4.46) |
Female sex, n (%) | 464 (59.7) | 231 (58.2) | 233 (61.3) | 231 (60.0) | 233 (59.4) | 233 (60.1) | 231 (59.4) |
BMI (kg m−2), mean (s.d.) | 25.72 (4.04) | 25.81 (4.13) | 25.63 (3.96) | 25.74 (3.94) | 25.70 (4.15) | 25.65 (3.96) | 25.80 (4.13) |
Years of education, mean (s.d.) | 13.48 (3.50) | 13.59 (3.64) | 13.37 (3.34) | 13.50 (3.31) | 13.47 (3.67) | 13.51 (3.45) | 13.46 (3.54) |
Healthy ager (NHS criteria), n (%) | 403 (52.3) | 212 (53.9) | 191 (50.5) | 211 (55.2) | 192 (49.4) | 200 (51.9) | 203 (52.6) |
Sangha comorbidity score60 (0–30 points), mean (s.d.) | 2.66 (2.58) | 2.66 (2.54) | 2.66 (2.63) | 2.57 (2.63) | 2.74 (2.53) | 2.64 (2.65) | 2.68 (2.51) |
25(OH)D <20 ng ml−1, n (%) | 263 (33.8) | 132 (33.2) | 131 (34.5) | 123 (31.9) | 140 (35.7) | 119 (30.7) | 144 (37.0) |
25(OH)D (ng ml−1), mean (s.d.) | 23.62 (8.44) | 23.76 (8.56) | 23.47 (8.31) | 23.80 (8.54) | 23.44 (8.33) | 24.17 (8.53) | 23.07 (8.32) |
Blood omega-3s (DHA + EPA) <100 ng ml−1, n (%) | 296 (38.1) | 152 (38.3) | 144 (37.9) | 144 (37.4) | 152 (38.8) | 140 (36.1) | 156 (40.1) |
Blood omega-3s (DHA + EPA) (ng ml−1), mean (s.d.) | 94.32 (40.12) | 93.40 (40.10) | 95.29 (40.17) | 94.63 (39.99) | 94.02 (40.30) | 92.25 (38.23) | 96.39 (41.87) |
Physical activity, n (%) | |||||||
Inactive | 93 (12.0) | 50 (12.6) | 43 (11.3) | 45 (11.7) | 48 (12.2) | 38 (9.8) | 55 (14.1) |
1–3 times per week | 227 (29.2) | 122 (30.7) | 105 (27.6) | 99 (25.7) | 128 (32.7) | 114 (29.4) | 113 (29.0) |
>3 times per week | 457 (58.8) | 225 (56.7) | 232 (61.1) | 241 (62.6) | 216 (55.1) | 236 (60.8) | 221 (56.8) |
